MCID: PNC041
MIFTS: 62

Pancreatic Ductal Adenocarcinoma

Categories: Endocrine diseases, Cancer diseases

Aliases & Classifications for Pancreatic Ductal Adenocarcinoma

MalaCards integrated aliases for Pancreatic Ductal Adenocarcinoma:

Name: Pancreatic Ductal Adenocarcinoma 38 12 14 69
Ductal Adenocarcinoma of the Pancreas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3498
NCIt 47 C9120
UMLS 69 C1335302

Summaries for Pancreatic Ductal Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that derives from pancreatic duct cells.

MalaCards based summary : Pancreatic Ductal Adenocarcinoma, also known as ductal adenocarcinoma of the pancreas, is related to pancreatic cancer and pancreatitis, and has symptoms including abdominal pain, icterus and pruritus. An important gene associated with Pancreatic Ductal Adenocarcinoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and Nanog in Mammalian ESC Pluripotency. The drugs Gemcitabine and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and lymph node, and related phenotypes are Decreased viability and cardiovascular system

Related Diseases for Pancreatic Ductal Adenocarcinoma

Diseases related to Pancreatic Ductal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
id Related Disease Score Top Affiliating Genes
1 pancreatic cancer 31.2 CDH1 CDKN2A EGFR TP53
2 pancreatitis 11.2
3 adenocarcinoma 11.2
4 microphthalmia/anophthalmia/coloboma spectrum 10.9 KRAS SMAD4 TP53
5 congenital mesoblastic nephroma 10.9 EGFR KRAS TP53
6 pediatric infratentorial ependymoma 10.9 EGFR TP53
7 cervical adenoid cystic carcinoma 10.9 CDKN2A TP53
8 multiple carboxylase deficiency 10.8 CDKN2A EGFR TP53
9 breast myoepithelial neoplasm 10.8 CTNNB1 KRAS TP53
10 malignant giant cell tumor of soft parts 10.8 CDKN2A EGFR PROM1
11 middle ear squamous cell carcinoma 10.8 CDKN2A EGFR TP53
12 secondary hyperparathyroidism of renal origin 10.8 CDKN2A EGFR TP53
13 rectum squamous cell carcinoma 10.8 AKT1 CDKN2A TP53
14 molluscum contagiosum 10.8 CDKN2A EGFR TP53
15 schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma 10.8 CDKN2A KRAS TP53
16 split-hand/foot malformation 4 10.8 CTNNB1 KRAS TP53
17 glycogen storage disease due to lactate dehydrogenase deficiency 10.8 CTNNB1 TP53
18 malignant skin fibrous histiocytoma 10.8 HRAS KRAS
19 spinal cord dermoid cyst 10.8 CTNNB1 EGFR TP53
20 cystic lymphangioma 10.8 CDKN2A EGFR TP53
21 severe pre-eclampsia 10.8 EGFR HRAS KRAS
22 rectum kaposi's sarcoma 10.8 CTNNB1 EGFR TP53
23 arteriolosclerosis 10.7 AKT1 CDKN2A MSLN
24 colon signet ring adenocarcinoma 10.7 CTNNB1 SMAD4 TP53
25 lacrimal gland mucoepidermoid carcinoma 10.7 CDH1 EGFR TP53
26 fallopian tube mucinous tumor 10.7 CDKN2A EGFR TP53
27 split hand split foot nystagmus 10.7 CDKN2A HRAS TP53
28 diffuse pulmonary fibrosis 10.7 HRAS KRAS SMAD4
29 extramedullary plasmacytoma 10.7 HRAS KRAS TP53
30 breast adenoid cystic carcinoma 10.7 EGFR HRAS KRAS
31 hypersensitivity reaction type iii disease 10.7 HRAS KRAS TP53
32 occupational dermatitis 10.7 EGFR HRAS KRAS
33 gestational choriocarcinoma 10.7 AKT1 MSLN TP53
34 olfactory neural tumor 10.7 CDKN2A HRAS TP53
35 ossifying fibromyxoid tumor 10.7 HRAS KRAS TP53
36 gorham's disease 10.7 EGFR HRAS KRAS
37 pancreatic serous cystic neoplasm 10.7 EGFR KRAS TP53
38 skin hemangioma 10.7 CTNNB1 PROM1 TP53
39 ductal carcinoma in situ 10.7 CDH1 CDKN2A EGFR TP53
40 anaerobic pneumonia 10.7 CDH1 CDKN2A EGFR TP53
41 renal pelvis urothelial papilloma 10.7 CDH1 TP53
42 cavernous sinus thrombosis 10.7 KRAS MUC1 TP53
43 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.7 CDKN2A EGFR MUC1
44 childhood type dermatomyositis 10.7 CDH1 CDKN2A EGFR TP53
45 hodgkin's lymphoma, mixed cellularity 10.7 CDH1 CDKN2A TP53
46 anuria 10.7 HRAS KRAS PROM1
47 orbital lymphangioma 10.6 CDH1 CDKN2A EGFR TP53
48 bleeding disorder, platelet-type, 13 10.6 CTNNB1 SMAD4 TP53
49 early congenital syphilis 10.6 EGFR HRAS KRAS
50 spastic ataxia 3 10.6 CDKN2A MUC1 TP53

Graphical network of the top 20 diseases related to Pancreatic Ductal Adenocarcinoma:



Diseases related to Pancreatic Ductal Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Ductal Adenocarcinoma

UMLS symptoms related to Pancreatic Ductal Adenocarcinoma:


abdominal pain, icterus, pruritus

GenomeRNAi Phenotypes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.88 EGFR HRAS KRAS MUC1
2 Decreased viability GR00106-A-0 9.88 KRAS
3 Decreased viability GR00221-A-1 9.88 EGFR HRAS KRAS AKT1 CDH1 CDKN2A
4 Decreased viability GR00221-A-2 9.88 HRAS KRAS AKT1
5 Decreased viability GR00221-A-3 9.88 HRAS AKT1 CDKN2A
6 Decreased viability GR00221-A-4 9.88 EGFR AKT1 CDKN2A
7 Decreased viability GR00301-A 9.88 KRAS CDH1
8 Decreased viability GR00381-A-1 9.88 KRAS
9 Decreased cell migration GR00055-A-1 9.43 AKT1 CTNNB1 EGFR HRAS KRAS MUC1

MGI Mouse Phenotypes related to Pancreatic Ductal Adenocarcinoma:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.37 HRAS KRAS PROM1 PTF1A SMAD4 TP53
2 homeostasis/metabolism MP:0005376 10.37 AKT1 AREG CDH1 CDKN2A CTNNB1 EGFR
3 growth/size/body region MP:0005378 10.35 CTNNB1 EGFR HRAS KRAS PROM1 PTF1A
4 behavior/neurological MP:0005386 10.34 AKT1 CDKN2A CTNNB1 HRAS KRAS PROM1
5 endocrine/exocrine gland MP:0005379 10.33 SMAD4 TP53 AKT1 AREG CDH1 CDKN2A
6 cellular MP:0005384 10.32 AKT1 CDH1 CDKN2A CTNNB1 EGFR KRAS
7 digestive/alimentary MP:0005381 10.22 AREG CDH1 CDKN2A CTNNB1 EGFR KRAS
8 embryo MP:0005380 10.21 AKT1 CDH1 CDKN2A CTNNB1 EGFR KRAS
9 integument MP:0010771 10.21 HRAS KRAS SMAD4 TP53 AKT1 AREG
10 neoplasm MP:0002006 10.2 AKT1 CDH1 CDKN2A CTNNB1 EGFR HRAS
11 nervous system MP:0003631 10.17 AKT1 CDKN2A CTNNB1 EGFR HRAS KRAS
12 craniofacial MP:0005382 10.12 HRAS KRAS PTF1A SMAD4 TP53 CTNNB1
13 normal MP:0002873 10.11 AKT1 CDH1 CTNNB1 EGFR HRAS KRAS
14 no phenotypic analysis MP:0003012 10.1 CDH1 CDKN2A CTNNB1 EGFR HRAS KRAS
15 liver/biliary system MP:0005370 10.08 AKT1 CDKN2A CTNNB1 EGFR KRAS PTF1A
16 limbs/digits/tail MP:0005371 10.04 PTF1A SLC29A1 SMAD4 TP53 CTNNB1 EGFR
17 reproductive system MP:0005389 9.96 AKT1 AREG CDH1 CDKN2A CTNNB1 EGFR
18 pigmentation MP:0001186 9.8 CDKN2A CTNNB1 EGFR KRAS PROM1 TP53
19 respiratory system MP:0005388 9.76 AKT1 CDKN2A CTNNB1 EGFR HRAS KRAS
20 skeleton MP:0005390 9.65 AKT1 CDKN2A CTNNB1 EGFR HRAS KRAS
21 vision/eye MP:0005391 9.23 AREG CDKN2A CTNNB1 EGFR KRAS PROM1

Drugs & Therapeutics for Pancreatic Ductal Adenocarcinoma

Drugs for Pancreatic Ductal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 1,Phase 2,Early Phase 1 95058-81-4 60750
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2,Early Phase 1 33069-62-4 36314
3
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
4
Pancrelipase Approved Phase 3,Phase 1,Phase 2,Early Phase 1 53608-75-6
5
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
6
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
7
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
8
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741 24759
9
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
11
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
12 acivicin Phase 3,Phase 2
13 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2,Early Phase 1
14 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Early Phase 1
15 Antimetabolites Phase 3,Phase 1,Phase 2,Early Phase 1
16 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2,Early Phase 1
17 Antimitotic Agents Phase 3,Phase 1,Phase 2,Early Phase 1
18 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2,Early Phase 1
19 Antiviral Agents Phase 3,Phase 1,Phase 2,Early Phase 1
20 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Early Phase 1
21 Protective Agents Phase 3,Phase 2,Phase 1
22 pancreatin Phase 3,Phase 1,Phase 2,Early Phase 1
23 Antidotes Phase 3,Phase 2
24 Micronutrients Phase 3,Phase 2,Phase 1
25 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
27 Trace Elements Phase 3,Phase 2,Phase 1
28 Vitamin B Complex Phase 3,Phase 2,Phase 1
29 Vitamins Phase 3,Phase 2,Phase 1
30 Adjuvants, Immunologic Phase 3
31 Viscosupplements Phase 3
32
Erlotinib Hydrochloride Phase 3,Phase 1,Phase 2 183319-69-9 176871
33 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
34 Hematinics Phase 3
35 Folate Nutraceutical Phase 3,Phase 2,Phase 1
36 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
37
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
38
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
39
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
40
Propofol Approved, Investigational, Vet_approved Phase 2,Phase 1 2078-54-8 4943
41
nivolumab Approved Phase 2,Phase 1 946414-94-4
42
Coal tar Approved Phase 1, Phase 2 8007-45-2
43
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
44
Olaparib Approved Phase 2 763113-22-0 23725625
45
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
46
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
47
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
48
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
49
Metformin Approved Phase 2 657-24-9 14219 4091
50
Camptothecin Experimental Phase 2,Phase 1 7689-03-4

Interventional clinical trials:

(show top 50) (show all 131)

id Name Status NCT ID Phase Drugs
1 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Not yet recruiting NCT02570529 Phase 4 Albis®;Placebo
2 A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenoca Recruiting NCT02715804 Phase 3 Placebo;Nab-paclitaxel;Gemcitabine
3 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
4 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
5 Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma Active, not recruiting NCT01526135 Phase 3 Arm B : mFolfirinox
6 Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Terminated NCT02101021 Phase 3 Momelotinib;Placebo to match momelotinib;Nab-paclitaxel;Gemcitabine
7 Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Unknown status NCT01893801 Phase 1, Phase 2 nab-paclitaxel;Cisplatin;gemcitabine
8 Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma Unknown status NCT01021800 Phase 2
9 Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Unknown status NCT02440958 Phase 2 modified FOLFIRINOX regimen
10 Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer Unknown status NCT02135822 Phase 2 nanoparticle albumin-bound paclitaxel;gemcitabine
11 Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
12 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Completed NCT01580397 Phase 2 INNO-206
13 A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation Completed NCT02042378 Phase 2 Rucaparib
14 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Completed NCT00585078 Phase 2 Capecitabine;Oxaliplatin
15 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed NCT01658943 Phase 2 Akt Inhibitor MK2206;Fluorouracil;Oxaliplatin;Selumetinib
16 Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
17 A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Recruiting NCT02981342 Phase 2 Abemaciclib;LY3023414;Gemcitabine;Capecitabine
18 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Recruiting NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
19 Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02426281 Phase 2 nab-paclitaxel;gemcitabine
20 Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02754726 Phase 2 Nivolumab;Albumin-bound paclitaxel;Paricalcitol;Cisplatin;Gemcitabine
21 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Recruiting NCT03193190 Phase 1, Phase 2 Nab-Paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Fluorouracil;Atezolizumab;Cobimetinib;PEGPH20;BL-8040
22 PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma Recruiting NCT02487277 Phase 2 PEGPH20;Gemcitabine;Nab-paclitaxel
23 A Phase II Study of Neoadjuvant FOLFIRINOX Recruiting NCT02178709 Phase 2 FOLFIRINOX
24 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
25 A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection Recruiting NCT03038477 Phase 2 Durvalumab
26 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Recruiting NCT02723331 Phase 2 Nab-paclitaxel and gemcitabine for R-PDAC Patients;Nab-paclitaxel and gemcitabine for BR-PDAC Patients
27 Study of NAC of GA Therapy for Patients With BRPC Recruiting NCT02926183 Phase 2 Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
28 Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Recruiting NCT02125136 Phase 2 Gem/nab-Pac;FOLFIFINOX
29 Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Recruiting NCT02047513 Phase 2 perioperative nab-paclitaxel/gemcitabine;adjuvant nab-paclitaxel/gemcitabine
30 Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Recruiting NCT02562898 Phase 1, Phase 2 Ibrutinib;Paclitaxel;Gemcitabine
31 Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer Recruiting NCT02806687 Phase 2 Gene Therapy product CYL-02;Gemcitabine
32 Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma Recruiting NCT02743975 Phase 1, Phase 2 Bevacizumab-800CW
33 Efficacy and Safety of PARPi to Treat Pancreatic Cancer Recruiting NCT02511223 Phase 2 OLAPARIB
34 A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors Recruiting NCT03267316 Phase 1, Phase 2
35 A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207) Recruiting NCT03085914 Phase 1, Phase 2 Epacadostat;Nivolumab;Pembrolizumab;Oxaliplatin;Leucovorin;5-Fluorouracil;Gemcitabine;nab-Paclitaxel;Carboplatin;Paclitaxel;Pemetrexed;Cyclophosphamide;Carboplatin
36 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
37 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Recruiting NCT02498613 Phase 2 Cediranib Maleate;Olaparib
38 Olaparib for BRCAness Phenotype in Pancreatic Cancer Recruiting NCT02677038 Phase 2 Olaparib
39 Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT02289898 Phase 2 Demcizumab;Abraxane®;gemcitabine;Placebo
40 Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients Active, not recruiting NCT02732938 Phase 2 PF-04136309;Nab-paclitaxel;Gemcitabine
41 Study of Tremelimumab in Patients With Advanced Solid Tumors Active, not recruiting NCT02527434 Phase 2
42 Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla Active, not recruiting NCT02626520 Phase 2 Gemcitabine and nanoparticle albumin bound paclitaxel;5-fluorouracil and irinotecan
43 Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer Active, not recruiting NCT02124317 Phase 2 nanoparticle albumin-bound paclitaxel;S-1
44 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Active, not recruiting NCT01280058 Phase 2 Carboplatin;Paclitaxel
45 Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma Active, not recruiting NCT01431794 Phase 1, Phase 2 LDE-225;Gemcitabine;nab-paclitaxel
46 The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma Not yet recruiting NCT02978547 Phase 2 Metformin Hydrochloride 500Mg Tablet
47 A Phase II Study of siG12D LODER in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer Not yet recruiting NCT01676259 Phase 2 siG12D-LODER;Gemcitabine+nab-Paclitaxel
48 High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain Suspended NCT00637364 Phase 1, Phase 2
49 Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) Terminated NCT01096732 Phase 2 GDC-0449
50 Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies Terminated NCT02109445 Phase 2 PF-03084014;Gemcitabine;Nab-paclitaxel;PF-03084014;Gemcitabine;Nab-paclitaxel;Gemcitabine;Nab-paclitaxel

Search NIH Clinical Center for Pancreatic Ductal Adenocarcinoma

Genetic Tests for Pancreatic Ductal Adenocarcinoma

Anatomical Context for Pancreatic Ductal Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Ductal Adenocarcinoma:

39
Pancreas, Lymph Node, T Cells, Liver, Testes, Neutrophil, Placenta
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Ductal Adenocarcinoma:
id Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Ducts Affected by disease

Publications for Pancreatic Ductal Adenocarcinoma

Articles related to Pancreatic Ductal Adenocarcinoma:

(show top 50) (show all 920)
id Title Authors Year
1
DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. ( 27959420 )
2017
2
Selective cytotoxicity of vanadium complexes on human pancreatic ductal adenocarcinoma cell line by inducing necroptosis, apoptosis and mitotic catastrophe process. ( 28947974 )
2017
3
Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma. ( 28912447 )
2017
4
MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-I_B Pathway In Vitro. ( 28194669 )
2017
5
Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients. ( 28056913 )
2017
6
Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance. ( 28279716 )
2017
7
Current Strategies for Detection and Treatment of Recurrence of Pancreatic Ductal Adenocarcinoma After Resection: A Nationwide Survey. ( 28902799 )
2017
8
Adipose Triglyceride Lipase (ATGL) Expression Is Associated with Adiposity and Tumor Stromal Proliferation in Patients with Pancreatic Ductal Adenocarcinoma. ( 28179319 )
2017
9
A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. ( 28350132 )
2017
10
Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-I^1/Gfi-1 axis. ( 27840243 )
2017
11
Lin28B facilitates the progression and metastasis of pancreatic ductal adenocarcinoma. ( 28947981 )
2017
12
Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma. ( 28220683 )
2017
13
Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma. ( 28060763 )
2017
14
Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. ( 28915633 )
2017
15
Invited Commentary on "Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT," with Response from Dr Zaky and Colleagues. ( 28076018 )
2017
16
Refining the American Joint Committee on Cancer Staging Scheme For Resectable Pancreatic Ductal Adenocarcinoma Using Recursive Partitioning Analysis. ( 28928865 )
2017
17
Clinical features of cystatin A expression in patients with pancreatic ductal adenocarcinoma. ( 28898495 )
2017
18
Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma. ( 28915602 )
2017
19
Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. ( 28062705 )
2017
20
Corrigendum to "Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis". ( 28912624 )
2017
21
Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. ( 28092365 )
2017
22
Melittin inhibits tumor growth and decreases resistance toA gemcitabine by downregulating cholesterol pathway geneA CLUA inA pancreatic ductal adenocarcinoma. ( 28428074 )
2017
23
The FOXO3/PGC-1I^ signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma. ( 28507102 )
2017
24
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. ( 28902789 )
2017
25
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. ( 28059968 )
2017
26
NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-I_B activation. ( 28951128 )
2017
27
Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma. ( 28915662 )
2017
28
Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. ( 28930665 )
2017
29
Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. ( 28187218 )
2017
30
Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma. ( 28921449 )
2017
31
CD25-expressing Th17 cells mediate CD8(+) T cell suppression in CTLA-4 dependent mechanisms in pancreatic ductal adenocarcinoma. ( 28942020 )
2017
32
Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma. ( 27814273 )
2017
33
KLF9 Is a Prognostic Indicator in Human Pancreatic Ductal Adenocarcinoma. ( 28668877 )
2017
34
KRAS Mutations With No GNAS Mutations in an Intraductal Papillary Mucinous Neoplasm: Are There Common Pathways With Pancreatic Ductal Adenocarcinoma? Lessons From an Extended IPMN, Covering the Entire Pancreas. ( 27977634 )
2017
35
SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-I_B axis. ( 28902358 )
2017
36
COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma. ( 27350032 )
2017
37
EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma. ( 27594424 )
2017
38
Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma. ( 28618924 )
2017
39
ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. ( 27862697 )
2017
40
APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma: Characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing. ( 28922540 )
2017
41
Histologic Tumor Grade and Preoperative Bilary Drainage are the Unique Independent Prognostic Factors of Survival in Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy. ( 28059940 )
2017
42
Microarray Analysis of the Expression Profile of Long Non-Coding RNAs Indicates lncRNA RP11-263F15.1 as a Biomarker for Diagnosis and Prognostic Prediction of Pancreatic Ductal Adenocarcinoma. ( 28928863 )
2017
43
Hypoxia induces oncogene yes-associated protein 1 nuclear translocation to promote pancreatic ductal adenocarcinoma invasion via epithelial-mesenchymal transition. ( 28475017 )
2017
44
Immunotherapy in Pancreatic Ductal Adenocarcinoma: An Emerging Entity? ( 28945842 )
2017
45
The clinicopathological significance of forkhead box P1 and forkhead box O3a in pancreatic ductal adenocarcinomas. ( 28466777 )
2017
46
Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway. ( 28315433 )
2017
47
Recent advances in proteomic profiling of pancreatic ductal adenocarcinoma and the road ahead. ( 28926720 )
2017
48
MiR-181b-5p, ETS1 and c-Met pathway exacerbates the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. ( 28064436 )
2017
49
DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics. ( 28339284 )
2017
50
Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma. ( 28653876 )
2017

Variations for Pancreatic Ductal Adenocarcinoma

Copy number variations for Pancreatic Ductal Adenocarcinoma from CNVD:

7 (show top 50) (show all 315)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14616 1 109662726 110421733 Loss Pancreatic ductal adenocarcinoma
2 14979 1 111694621 112653686 Loss Pancreatic ductal adenocarcinoma
3 15141 1 11296895 11700048 Loss Pancreatic ductal adenocarcinoma
4 15254 1 113902673 114772618 Loss Pancreatic ductal adenocarcinoma
5 21071 1 156591077 157602759 Gain Pancreatic ductal adenocarcinoma
6 22927 1 16990962 17780550 Loss Pancreatic ductal adenocarcinoma
7 23665 1 172632928 173462394 Gain Pancreatic ductal adenocarcinoma
8 23983 1 174098656 174792564 Gain Pancreatic ductal adenocarcinoma
9 24268 1 17780550 18767187 Loss Pancreatic ductal adenocarcinoma
10 25340 1 18767187 19870518 Loss Pancreatic ductal adenocarcinoma
11 25429 1 189012940 189640525 Gain Pancreatic ductal adenocarcinoma
12 25525 1 190940606 191897513 Gain Pancreatic ductal adenocarcinoma
13 25603 1 191897513 192833019 Gain Pancreatic ductal adenocarcinoma
14 25668 1 192833019 193928417 Gain Pancreatic ductal adenocarcinoma
15 25957 1 195125528 196179631 Gain Pancreatic ductal adenocarcinoma
16 26123 1 197274194 198251428 Gain Pancreatic ductal adenocarcinoma
17 26286 1 19870518 21264484 Loss Pancreatic ductal adenocarcinoma
18 27649 1 210637543 211466127 Gain Pancreatic ductal adenocarcinoma
19 29512 1 232834654 234059648 Gain Pancreatic ductal adenocarcinoma
20 29988 1 23881482 24596143 Loss Pancreatic ductal adenocarcinoma
21 30783 1 24596143 24901021 Loss Pancreatic ductal adenocarcinoma
22 31049 1 24901021 26202341 Loss Pancreatic ductal adenocarcinoma
23 31229 1 26202341 27453508 Loss Pancreatic ductal adenocarcinoma
24 31475 1 27702974 28279739 Loss Pancreatic ductal adenocarcinoma
25 31649 1 29154418 29949616 Loss Pancreatic ductal adenocarcinoma
26 31710 1 29949616 31202941 Loss Pancreatic ductal adenocarcinoma
27 31822 1 31202941 32179980 Loss Pancreatic ductal adenocarcinoma
28 32104 1 33581730 34569385 Loss Pancreatic ductal adenocarcinoma
29 32211 1 34569385 35804738 Loss Pancreatic ductal adenocarcinoma
30 32498 1 36953732 37599763 Loss Pancreatic ductal adenocarcinoma
31 32649 1 38143717 38830556 Loss Pancreatic ductal adenocarcinoma
32 32759 1 3913633 5229374 Loss Pancreatic ductal adenocarcinoma
33 33297 1 44268667 45000776 Loss Pancreatic ductal adenocarcinoma
34 33745 1 47532872 48556325 Loss Pancreatic ductal adenocarcinoma
35 34094 1 5229374 6509870 Loss Pancreatic ductal adenocarcinoma
36 34199 1 53371440 53750907 Loss Pancreatic ductal adenocarcinoma
37 34230 1 53750907 54788971 Loss Pancreatic ductal adenocarcinoma
38 36948 1 8379388 9142502 Loss Pancreatic ductal adenocarcinoma
39 37455 1 9142502 9661749 Loss Pancreatic ductal adenocarcinoma
40 38508 10 103075332 103271952 Gain Pancreatic ductal adenocarcinoma
41 41307 10 15917593 17007248 Gain Pancreatic ductal adenocarcinoma
42 41728 10 22854210 23744923 Gain Pancreatic ductal adenocarcinoma
43 44446 10 57203760 58367659 Gain Pancreatic ductal adenocarcinoma
44 44911 10 64846281 66342495 Gain Pancreatic ductal adenocarcinoma
45 45553 10 72143312 73316160 Loss Pancreatic ductal adenocarcinoma
46 45655 10 73316160 74391172 Gain Pancreatic ductal adenocarcinoma
47 45775 10 74391172 75333936 Gain Pancreatic ductal adenocarcinoma
48 45937 10 75333936 76299818 Gain Pancreatic ductal adenocarcinoma
49 46231 10 79273961 80171344 Loss Pancreatic ductal adenocarcinoma
50 46288 10 80171344 81279277 Loss Pancreatic ductal adenocarcinoma

Expression for Pancreatic Ductal Adenocarcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Pancreatic Ductal Adenocarcinoma patients vs. healthy controls: 35 (show top 50) (show all 375)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SYCN syncollin Pancreas - 8.04 0.000
2 GP2 glycoprotein 2 (zymogen granule membrane) Pancreas - 7.99 0.000
3 ALB albumin Pancreas - 7.95 0.000
4 SERPINI2 serpin peptidase inhibitor, clade I (pancpin), member 2 Pancreas - 7.95 0.000
5 CELA2B chymotrypsin-like elastase family, member 2B Pancreas - 7.74 0.000
6 PNLIPRP1 pancreatic lipase-related protein 1 Pancreas - 7.66 0.000
7 PDIA2 protein disulfide isomerase family A, member 2 Pancreas - 7.53 0.000
8 SPX spexin hormone Pancreas - 7.53 0.000
9 CTRL chymotrypsin-like Pancreas - 7.52 0.000
10 COL10A1 collagen, type X, alpha 1 Pancreas + 7.52 0.000
11 CELP carboxyl ester lipase pseudogene Pancreas - 7.50 0.000
12 COL5A1 collagen, type V, alpha 1 Pancreas + 7.46 0.000
13 SULF1 sulfatase 1 Pancreas + 7.38 0.000
14 CUZD1 CUB and zona pellucida-like domains 1 Pancreas - 7.29 0.000
15 POSTN periostin, osteoblast specific factor Pancreas + 7.24 0.000
16 COL1A1 collagen, type I, alpha 1 Pancreas + 7.17 0.000
17 AQP8 aquaporin 8 Pancreas - 7.14 0.000
18 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 Pancreas + 7.10 0.000
19 COL11A1 collagen, type XI, alpha 1 Pancreas + 7.00 0.000
20 CLPS colipase, pancreatic Pancreas - 6.99 0.000
21 INHBA inhibin, beta A Pancreas + 6.95 0.000
22 CPA2 carboxypeptidase A2 (pancreatic) Pancreas - 6.88 0.000
23 CTRC chymotrypsin C (caldecrin) Pancreas - 6.87 0.000
24 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) Pancreas + 6.86 0.000
25 PLA2G1B phospholipase A2, group IB (pancreas) Pancreas - 6.79 0.001
26 COL3A1 collagen, type III, alpha 1 Pancreas + 6.78 0.000
27 SFRP4 secreted frizzled-related protein 4 Pancreas + 6.76 0.000
28 CELA3A chymotrypsin-like elastase family, member 3A Pancreas - 6.76 0.001
29 GNMT glycine N-methyltransferase Pancreas - 6.74 0.000
30 COL1A2 collagen, type I, alpha 2 Pancreas + 6.72 0.000
31 REG1P regenerating islet-derived 1 pseudogene Pancreas - 6.72 0.000
32 S100P S100 calcium binding protein P Pancreas + 6.67 0.000
33 CELA3B chymotrypsin-like elastase family, member 3B Pancreas - 6.66 0.001
34 CEL carboxyl ester lipase Pancreas - 6.63 0.001
35 CTHRC1 collagen triple helix repeat containing 1 Pancreas + 6.60 0.000
36 CPA1 carboxypeptidase A1 (pancreatic) Pancreas - 6.56 0.001
37 VCAN versican Pancreas + 6.51 0.000
38 TMEM52 transmembrane protein 52 Pancreas - 6.40 0.000
39 REG1B regenerating islet-derived 1 beta Pancreas - 6.35 0.002
40 CTSE cathepsin E Pancreas + 6.30 0.000
41 GLS2 glutaminase 2 (liver, mitochondrial) Pancreas - 6.28 0.000
42 KLK1 kallikrein 1 Pancreas - 6.26 0.000
43 GJB2 gap junction protein, beta 2, 26kDa Pancreas + 6.24 0.000
44 REG3G regenerating islet-derived 3 gamma Pancreas - 6.17 0.000
45 PLAU plasminogen activator, urokinase Pancreas + 6.15 0.000
46 COL5A2 collagen, type V, alpha 2 Pancreas + 6.13 0.000
47 SLC39A5 solute carrier family 39 (zinc transporter), member 5 Pancreas - 6.09 0.000
48 ERP27 endoplasmic reticulum protein 27 Pancreas - 6.07 0.000
49 SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C Pancreas + 6.00 0.000
50 PNLIP pancreatic lipase Pancreas - 5.94 0.004
Search GEO for disease gene expression data for Pancreatic Ductal Adenocarcinoma.

Pathways for Pancreatic Ductal Adenocarcinoma

Pathways related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 87)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 AKT1 AREG CDH1 CDKN2A CTNNB1 EGFR
2
Show member pathways
13.34 AKT1 AREG CDH1 CTNNB1 EGFR HRAS
3
Show member pathways
13.34 AKT1 AREG CDH1 CTNNB1 EGFR HRAS
4
Show member pathways
13.13 AKT1 AREG EGFR HRAS KRAS TP53
5
Show member pathways
13.05 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
6
Show member pathways
12.94 AKT1 CTNNB1 HRAS KRAS TP53
7
Show member pathways
12.84 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
8
Show member pathways
12.82 AKT1 CTNNB1 EGFR HRAS KRAS
9
Show member pathways
12.79 AKT1 EGFR HRAS KRAS TP53
10 12.78 AKT1 EGFR HRAS KRAS TP53
11
Show member pathways
12.76 AKT1 CDH1 CTNNB1 EGFR HRAS KRAS
12 12.75 AKT1 CTNNB1 EGFR HRAS KRAS TP53
13
Show member pathways
12.72 AKT1 EGFR HRAS KRAS TP53
14
Show member pathways
12.63 AKT1 CTNNB1 EGFR HRAS KRAS TP53
15 12.57 CDKN2A EGFR HRAS KRAS TP53
16 12.57 AKT1 CDH1 CDKN2A CTNNB1 EGFR HRAS
17
Show member pathways
12.56 AKT1 EGFR HRAS KRAS TP53
18
Show member pathways
12.54 AKT1 CDH1 CDKN2A CTNNB1 EGFR HRAS
19
Show member pathways
12.47 AKT1 CTNNB1 EGFR HRAS KRAS TP53
20
Show member pathways
12.46 AKT1 EGFR HRAS KRAS
21
Show member pathways
12.46 AKT1 CTNNB1 HRAS KRAS
22
Show member pathways
12.45 AKT1 CTNNB1 EGFR HRAS KRAS
23
Show member pathways
12.42 CTNNB1 HRAS KRAS TP53
24 12.42 CDH1 CDKN2A SMAD4 TP53
25
Show member pathways
12.41 AKT1 EGFR HRAS KRAS
26 12.41 AKT1 CDKN2A CTNNB1 HRAS KRAS SMAD4
27 12.35 CDKN2A HRAS KRAS TP53
28
Show member pathways
12.35 AKT1 EGFR HRAS KRAS
29
Show member pathways
12.32 AKT1 AREG EGFR HRAS KRAS TP53
30
Show member pathways
12.31 AKT1 EGFR HRAS KRAS TP53
31 12.29 AKT1 CTNNB1 EGFR HRAS KRAS TP53
32
Show member pathways
12.27 AKT1 HRAS KRAS TP53
33
Show member pathways
12.27 AKT1 AREG EGFR HRAS KRAS
34 12.24 AKT1 EGFR HRAS KRAS
35
Show member pathways
12.23 AKT1 HRAS KRAS TP53
36 12.21 AREG CDH1 CTNNB1 SMAD4
37
Show member pathways
12.2 AKT1 HRAS KRAS TP53
38
Show member pathways
12.2 AKT1 EGFR HRAS KRAS
39
Show member pathways
12.19 AKT1 HRAS KRAS TP53
40 12.19 AKT1 CDH1 CTNNB1 EGFR KRAS SMAD4
41
Show member pathways
12.17 AKT1 CTNNB1 EGFR HRAS
42 12.15 AKT1 CTNNB1 HRAS KRAS SMAD4
43
Show member pathways
12.14 AKT1 EGFR HRAS KRAS SMAD4
44 12.14 AKT1 CDH1 CTNNB1 EGFR KRAS SMAD4
45 12.13 AKT1 CDKN2A KRAS TP53
46 12.13 AKT1 CDH1 HRAS KRAS SMAD4
47 12.12 CDKN2A CTNNB1 SMAD4 TP53
48
Show member pathways
12.12 AKT1 EGFR HRAS KRAS
49
Show member pathways
12.11 AKT1 AREG CDH1 CTNNB1 EGFR HRAS
50
Show member pathways
12.1 AKT1 EGFR HRAS KRAS TP53

GO Terms for Pancreatic Ductal Adenocarcinoma

Cellular components related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 catenin complex GO:0016342 9.16 CDH1 CTNNB1
2 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
3 vesicle GO:0031982 8.92 AKT1 MUC1 MUC4 PROM1

Biological processes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.98 CDKN2A CTNNB1 HRAS SMAD4 TP53
2 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.97 AKT1 CDKN2A CTNNB1 EGFR HRAS PTF1A
3 positive regulation of apoptotic process GO:0043065 9.93 AKT1 CDKN2A CTNNB1 NUPR1 TP53
4 positive regulation of gene expression GO:0010628 9.85 CTNNB1 HRAS KRAS TP53
5 positive regulation of protein phosphorylation GO:0001934 9.83 AKT1 EGFR HRAS KRAS
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.76 HRAS KRAS MUC1 MUC4
7 positive regulation of transcription, DNA-templated GO:0045893 9.76 AKT1 CDH1 CDKN2A CTNNB1 EGFR PTF1A
8 positive regulation of MAP kinase activity GO:0043406 9.75 EGFR HRAS KRAS
9 cellular response to growth factor stimulus GO:0071363 9.73 AKT1 CTNNB1 EGFR
10 positive regulation of cell proliferation GO:0008284 9.73 AREG CTNNB1 EGFR HRAS KRAS SLC35F6
11 positive regulation of DNA replication GO:0045740 9.67 AREG EGFR HRAS
12 ERBB2 signaling pathway GO:0038128 9.65 EGFR HRAS KRAS
13 replicative senescence GO:0090399 9.62 CDKN2A TP53
14 Ras protein signal transduction GO:0007265 9.62 CDKN2A HRAS KRAS TP53
15 entry of bacterium into host cell GO:0035635 9.61 CDH1 CTNNB1
16 positive regulation of cellular senescence GO:2000774 9.61 CDKN2A KRAS
17 retina morphogenesis in camera-type eye GO:0060042 9.6 PROM1 PTF1A
18 response to isolation stress GO:0035900 9.59 HRAS KRAS
19 pancreas development GO:0031016 9.58 CTNNB1 MSLN PTF1A
20 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.57 AKT1 EGFR
21 cellular response to indole-3-methanol GO:0071681 9.51 CDH1 CTNNB1
22 cell proliferation GO:0008283 9.5 AKT1 AREG CTNNB1 EGFR HRAS SMAD4
23 response to UV-A GO:0070141 9.43 AKT1 EGFR
24 epidermal growth factor receptor signaling pathway GO:0007173 8.92 AREG EGFR HRAS KRAS

Molecular functions related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.72 AKT1 CDKN2A CTNNB1 EGFR TP53
2 protein phosphatase binding GO:0019903 9.54 CTNNB1 EGFR TP53
3 RNA polymerase II transcription factor binding GO:0001085 9.43 CTNNB1 SMAD4 TP53
4 I-SMAD binding GO:0070411 9.4 CTNNB1 SMAD4
5 nitric-oxide synthase regulator activity GO:0030235 9.16 AKT1 EGFR
6 chromatin binding GO:0003682 9.1 CTNNB1 EGFR NUPR1 PTF1A SMAD4 TP53
7 disordered domain specific binding GO:0097718 8.96 CTNNB1 TP53

Sources for Pancreatic Ductal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....